AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGRAF) (“HydroGraph” or the “Company”) today announced the appointment of John Neale as Chief Financial Officer, effective February 20, 2026. Matt Anderson, who previously served as Chief Financial Officer, will continue serving the Company in the role of Vice President of Finance. As CFO, Mr. Neale will oversee HydroGraph’s finance, legal, human resources and technology teams, bringing more than 20 years of finan ...

Management outlines operational focus, capital positioning and strategic directionMIAMI, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- RenX Enterprises Corp. (NASDAQ: RENX) (“RenX” or the “Company”) today issued a letter to shareholders providing an update on operational focus, capital positioning, and strategic direction, all designed to strengthen the Company’s long-term performance. RenX’s letter to shareholders follows below. Dear Fellow Shareholders, As we move further into RenX’s transformation, we would like ...

Core Insights - JAKKS Pacific, Inc. has launched a next-generation cultural platform focused on anime, manga, and digital creators, marking a significant strategic initiative for the company [3][4] - This investment positions JAKKS at the forefront of a rapidly growing segment in global entertainment, aiming for sustained global growth and long-term shareholder value [4][6] Strategic Partnerships and Product Offerings - The platform will involve collaborations with top-tier partners across various sectors, including fandom engagement, licensing, and live entertainment, to create a diverse portfolio of collectibles and products [5][9] - Initial product launches are expected in 2027, with further details on partnerships and product lines to be announced throughout 2026 [10] Market Opportunities - JAKKS identifies a significant opportunity in live-event and influencer merchandising, targeting high-growth markets that have previously lacked premium product offerings [7] - The company aims to enhance consumer engagement and capitalize on record levels of interest in anime and manga [7] Distribution Strategy - A new global distribution infrastructure is being implemented to improve speed-to-market and expand reach across various consumer touchpoints [8] - This multi-layered network will include direct-to-consumer and experiential retail channels [8] Long-term Growth Strategy - The initiative represents a fundamental evolution in JAKKS' growth strategy, focusing on building a durable platform that can outperform traditional product cycles [9] - The company emphasizes its commitment to innovation and operational excellence in expanding its brand leadership [9]

Core Insights - Flywire Corporation has appointed Patrick Blanc as Chief Technology Officer to lead its global engineering and technology strategy, enhancing its AI-first engineering approach and scaling to meet client demand [1][2][3] Company Overview - Flywire is a global payments enablement and software company that combines a proprietary global payments network with next-gen payments platform and vertical-specific software to facilitate complex payments for clients [4] - The company supports over 4,900 clients with diverse payment methods in more than 140 currencies across 240 countries and territories [5] Leadership Changes - Patrick Blanc's appointment comes as David King transitions to a new role as Chief Product Officer and Co-President of Global Education, highlighting Flywire's commitment to product innovation and scaling software capabilities [3]

Core Viewpoint - AIM ImmunoTech Inc. is advancing its Phase 2 clinical study of Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, with promising early results and a commitment to ongoing updates [1][2][4]. Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial with 18 subjects enrolled, focusing on patients with stable disease post-FOLFIRINOX [2]. - The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center, with interim progress reports planned for mid-year and year-end [2]. - The lead investigator reported continued promising results in Progression-Free Survival and Overall Survival from Phase 1, supporting the ongoing Phase 2 study [2]. Group 2: Safety and Quality of Life - There has been no significant toxicity reported, indicating a favorable safety profile for Ampligen in a post-chemotherapy setting [3]. - Subjects receiving Ampligen have consistently reported a "high quality of life" during treatment [3]. Group 3: Future Milestones - Key milestones include completing subject enrollment by July 2026, full dosing by August 2026, and evaluating primary and secondary endpoints by December 2026 and June 2027, respectively [5]. - The primary endpoint is the Clinical Benefit Rate at 6 months, while secondary endpoints include Progression-Free Survival, Overall Survival, and immunogenic efficacy [5]. Group 4: Corporate Strategy - AIM emphasizes the potential for Ampligen's approval in pancreatic cancer, viewing this research as a significant opportunity for stockholders [4]. - The company aims to advance Ampligen towards Phase 3 clinical trials, which are often associated with substantial financial opportunities in the biotech sector [4].

Core Viewpoint - Glunz & Jensen Holding A/S has approved its financial outlook for 2026, indicating stable revenue and profit expectations compared to 2025 [1][3]. Financial Outlook - The expected revenue for 2026 is approximately DKK 140 million, which remains unchanged from the outlook for 2025 [3]. - The expected EBITDA for 2026 is approximately DKK 18 million, an increase from the outlook for 2025 which was approximately DKK 17 million [3]. - The expected profit before tax for 2026 is approximately DKK 12 million, up from the outlook for 2025 which was approximately DKK 11 million [3]. Additional Information - The outlook for 2026 is not influenced by the selling process of Selandia Park A/S [3]. - The annual report for 2025 is scheduled to be announced on March 17, 2026 [3].

Core Viewpoint - Akari Therapeutics has appointed Dr. Olga Anczukow to its Scientific Advisory Board, enhancing its expertise in RNA biology and cancer research, which is crucial for the development of next-generation therapeutics [1][2][4] Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with a unique payload, PH1, that targets RNA splicing in cancer cells [9] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [9] - AKTX-101 has shown significant activity in preclinical studies, demonstrating prolonged survival compared to traditional ADCs and potential synergy with checkpoint inhibitors [9] Dr. Olga Anczukow's Background - Dr. Anczukow is a recognized leader in RNA biology and cancer research, currently serving as an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center [4][6] - Her research focuses on alternative RNA splicing and its misregulation in cancer, contributing to tumor initiation, progression, and therapeutic resistance [4][6] - Dr. Anczukow's previous work includes significant contributions to understanding breast cancer genetics and the role of RNA splicing in cancer biology [5][6] Research and Development Focus - The company aims to leverage Dr. Anczukow's expertise to shape research strategy and evaluate emerging scientific opportunities, particularly in RNA-targeted treatments [2][4] - Akari's innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific antigen targets [9] - The ongoing research at The Jackson Laboratory integrates various methodologies to investigate how cancer cells adapt their splicing programs to survive and evade therapy [6]

Core Insights - Capgemini has formed a strategic partnership with OpenAI to enhance enterprise AI transformation through the Frontier platform, focusing on addressing business, data, and integration challenges [1][4] - The partnership aims to leverage Capgemini's industry expertise and OpenAI's advanced AI capabilities to create integrated solutions that drive measurable business outcomes [2][5] Group 1: Partnership Details - Capgemini is a founding member of the OpenAI Frontier Alliance, which will help businesses deploy AI securely and reliably across their operations [1][4] - The collaboration will establish a dedicated OpenAI Enterprise Frontier delivery function, comprising AI experts to support clients in scaling AI operations [4] Group 2: Market Context - 2026 is identified as a pivotal year for AI, with over half of organizations committing to long-term investments, shifting focus from experimentation to value creation [3] - The primary barrier to scaling AI is now recognized as the readiness of data and operating models rather than the technology itself [3] Group 3: Strategic Implications - The partnership is seen as a critical moment for enterprises, as organizations must scale AI to maintain competitive advantage [5] - Capgemini and OpenAI will co-develop industry-specific solutions targeting sectors such as consumer products, financial services, life sciences, and energy [4]

Core Viewpoint - Globex Mining Enterprises Inc. is updating shareholders on exploration drilling by Cartier Resources Inc. on Globex's Nordeau Royalty claims, highlighting the discovery of a new gold zone called the East Nordeau Zone, which is part of an aggressive drilling program [1][2]. Group 1: Exploration and Drilling Results - Cartier Resources has reported significant high-grade gold mineralization in the East Nordeau Zone (ENZ), which consists of two parallel high-grade gold zones, EN1 and EN2, with a confirmed strike length of 400 meters and open to depth [2][4]. - The ENZ is located 800 meters south of the Contact Sector and the high-grade North Contact Zone, indicating potential for further gold discoveries in the Nordeau Sector [2][4]. - Notable drill results include: - CA25-565: 23.2 g/t Au over 1.0 meters in EN1 Zone - CA25-570: 11.9 g/t Au over 1.0 meters in EN1 Zone and 14.1 g/t Au over 1.0 meters in EN2 Zone - CA25-572: 7.3 g/t Au over 1.0 meters in EN1 Zone [5]. Group 2: Future Plans and Expectations - Cartier plans further drilling to refine the geological model and verify the continuity of mineralization, with exploration drilling aimed at testing several new high-priority regional targets along the Nordeau Sector and the Cadillac Fault Zone [4][9]. - The success of Cartier's drilling on Globex's royalty claims is viewed positively, with anticipation for additional results from the North Contact Zone and the East Nordeau Zone as the drilling program progresses [9].

Core Insights - Palisade Bio, Inc. presented new translational data for PALI-2108, a targeted oral PDE4 inhibitor prodrug, at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, demonstrating localized target engagement and early clinical response within seven days [1][2][10] Group 1: Clinical Findings - In a Phase 1b trial involving patients with moderate-to-severe ulcerative colitis (UC), PALI-2108 achieved a 100% clinical response rate, with 40% of patients reaching clinical remission as measured by the modified Mayo Score [5][9] - The treatment resulted in significant downregulation of inflammatory and fibrosis-associated gene expression programs, including suppression of TNF-α, JAK–STAT, NF-κB, MAPK, and TGF-β pathways [5][6] - Histologic improvements were observed alongside reductions in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) levels, indicating a decrease in inflammation [5][6] Group 2: Mechanism of Action - PALI-2108 is designed for localized delivery to the terminal ileum and colon, where it is bioactivated by bacterial enzymes, allowing for targeted PDE4 inhibition at sites of inflammation while minimizing systemic exposure [7][9] - The prodrug's pharmacological activity was confirmed through RNA sequencing and pathway analyses, which showed localized suppression of inflammatory signaling networks in colonic tissue, with peripheral immune profiles remaining largely unchanged [4][6] Group 3: Safety and Tolerability - The safety profile of PALI-2108 was encouraging, with no serious adverse events reported among the 89 subjects in the study, supporting its potential as a differentiated treatment option for inflammatory bowel diseases [1][9] - The localized pharmacology of PALI-2108 aims to improve tolerability by reducing common side effects associated with systemic PDE4 inhibitors, such as diarrhea, nausea, and headache [7][8] Group 4: Future Development - Palisade Bio is advancing PALI-2108 into a Phase 2 clinical study to evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with plans for an extension phase to assess maintenance of remission [10]